Expressing the sense of Congress that governmental entities should use a portion of the proceeds from litigation against opioid manufacturers and distributors to increase participation in drug take back programs and for the safe disposal of collected, unused medicines.
USA117th CongressHCONRES-42| House
| Updated: 7/22/2021
David B. McKinley
Republican Representative
West Virginia
Cosponsors (17)
Tim Ryan (Democratic)Chris Pappas (Democratic)David J. Trone (Democratic)Mariannette Miller-Meeks (Republican)William R. Timmons (Republican)Madeleine Dean (Democratic)Jeff Duncan (Republican)Angie Craig (Democratic)Andrew R. Garbarino (Republican)J. French Hill (Republican)Mark DeSaulnier (Democratic)Joe Wilson (Republican)Rodney Davis (Republican)Nancy Mace (Republican)Raja Krishnamoorthi (Democratic)Brian K. Fitzpatrick (Republican)Harold Rogers (Republican)
Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
This concurrent resolution expresses the sense of Congress that government entities should consider using a portion of proceeds from litigation against opioid manufacturers and distributors for drug take-back programs.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Health
Civil actions and liabilityConsumer affairsDrug trafficking and controlled substancesPrescription drugsSolid waste and recyclingState and local financeState and local government operationsTransportation costs
Expressing the sense of Congress that governmental entities should use a portion of the proceeds from litigation against opioid manufacturers and distributors to increase participation in drug take back programs and for the safe disposal of collected, unused medicines.
USA117th CongressHCONRES-42| House
| Updated: 7/22/2021
This concurrent resolution expresses the sense of Congress that government entities should consider using a portion of proceeds from litigation against opioid manufacturers and distributors for drug take-back programs.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
David B. McKinley
Republican Representative
West Virginia
Cosponsors (17)
Tim Ryan (Democratic)Chris Pappas (Democratic)David J. Trone (Democratic)Mariannette Miller-Meeks (Republican)William R. Timmons (Republican)Madeleine Dean (Democratic)Jeff Duncan (Republican)Angie Craig (Democratic)Andrew R. Garbarino (Republican)J. French Hill (Republican)Mark DeSaulnier (Democratic)Joe Wilson (Republican)Rodney Davis (Republican)Nancy Mace (Republican)Raja Krishnamoorthi (Democratic)Brian K. Fitzpatrick (Republican)Harold Rogers (Republican)
Health Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Civil actions and liabilityConsumer affairsDrug trafficking and controlled substancesPrescription drugsSolid waste and recyclingState and local financeState and local government operationsTransportation costs